Prospective, randomized, open-label, clinical trial comparing the effects of dapagliflozin and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000032705
- Lead Sponsor
- Tokorozawa Heart Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Allergy against dapagliflozin/sitagliptin 2) Type I diabetes 3) Secondary diabetes 4) Poor-controlled diabetes (HbA1c>10.0 %) 5) Subjects who takes GLP-1 receptor agonist or DPP4 inhibitor. 6)History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 7) Either level of aspartate aminotransaminase or alanine aminotransferase exceed three-fold of the normal limits 8) renal insufficiency: serum creatinine>1.3 (male)>1.2(female) 9) Symptomatic (NYHA III or IV) congestive heart failure 10) Malignancies or other diseases with poor prognosis 11) Pregnant 12) Subjects whose doctor in charge do not agree to join the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method